AEHR · Aehr Test SystemsAehr Test Systems

AEHR transitioning from qualification to mass volume with hyperscale customer orders, confirmed by backlog, guidance, and explicit statements about volume ramp and follow-on orders.

AEHR confirmed near term production ramp and significant follow up orders, indicating bullish revenue growth.

Near term volume ramp from a hyperscaler is bullish for AEHR, though current financials reflect qualification cycles and not yet the ramp.

AEHR's potential major optical customer orders may not appear immediately due to qualification cycles, but mass order ramp for 2027 will be priced in now.

AEHR expected to re-rate based on future mass orders in 2027 with indications from upcoming earnings call, similar to AAOI's re-rating after signaling future revenue.

$AEHR has received significant forecasts from lead hyperscale customer for Sonoma systems indicating mass order, which will be clarified in upcoming earnings call.

AEHR is in early stages with many hyperscalers testing; as customers move from testing to mass production, it will drive multi-year revenue growth. Current financials are less important than customer profile and production expansion indicators.

Bullish on photonics and laser exposure plays, with highest upside in SIVE.

Bears misunderstand qualification cycles in semi names, focusing only on current revenue numbers, leading to underestimation of AEHR's potential.

Higher concentration on AEHR after new silicon photonics T1 customer (like LITE, AVGO, COHR), as retail shorts misunderstand qualification cycles and will face losses in a supercycle.

Shorts by IREN investors are adding fuel to the fire for AEHR's bullish move due to misunderstood qualification cycles in semiconductor names.

Predicts $AEHR market cap reaching $10B in 1.5 years.

AEHR's rapid price increase is attributed to ongoing qualification cycles and volume ramp from hyperscalers testing orders, contrary to short-sellers focusing on current revenue.

Silicon photonics scaling faces wafer testing bottleneck, benefiting testing companies.

AEHR received a $41M production order from its lead hyperscaler customer, confirming an anticipated volume ramp.

Reaffirms long-term bullish thesis on a basket of semiconductor and related stocks, noting that short-term entry points vary but overall market validation continues.

Upstream photonics supply chain is concentrated in Asia; US-listed equities like AAOI and AEHR are rare, overlooked opportunities in the 1.6T/CPO supercycle.

AEHR is used by hyperscalers and as market cap grows, institutions drive price, leading to a repricing.

AEHR is very early in its long-term story, having only started volume ramp with one customer. Additional customers (like their T1 optical transceiver) will pick up over the next few years, making it a long-term opportunity. However, near-term valuations are more priced in.

Algorithms are tying $SIVE, $AAOI, and $AEHR to $LITE as the sector leader, causing them to rise together following LITE's inclusion in the Nasdaq 100 and subsequent inflow.